Company news

Ocular Therapeutix, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocular Therapeutix™ Reports First Quarter 2020 Financial Results and Business Update

May 7, 2020

Ocular Therapeutix™ To Report First Quarter 2020 Financial Results

April 29, 2020

Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

April 27, 2020

Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic

April 12, 2020

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update

March 11, 2020

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results

March 4, 2020

Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference

March 2, 2020

Ocular Therapeutix Announces Strategic Update and Operational Restructuring

November 7, 2019

Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results

November 4, 2019

Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

September 30, 2019

Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis

September 23, 2019

← Newer news releases

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.